Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

R. Collins | S. Cosgrove | P. Libby | P. Pais | J. Varigos | P. Ridker | K. Bailey | B. Gersh | R. Glynn | K. Seung | M. Flather | A. Budaj | H. Krum | G. McMahon | J. Kastelein | H. Rugo | R. Blumenthal | W. Koenig | V. Fowler | C. Ballantyne | A. Limaye | D. Levine | J. Cornel | P. Sinnaeve | J. Gralow | R. Cífková | H. Burris | M. Donath | H. Shimokawa | N. Rost | A. Singhal | D. Pella | N. Gotcheva | M. Dellborg | D. Miličić | A. Fucili | J. Nicolau | H. Ogawa | B. Everett | B. Maron | N. Ghosh | P. Commerford | S. Chou | H. Colhoun | A. Manolis | E. Bohula | M. Ning | A. Pradhan | S. Bilazarian | J. Macfadyen | F. Fonseca | J. Genest | A. Lorenzatti | J. Danik | A. Cioffi | V. Taqueti | B. Olenchock | M. Urina-Triana | Juey-Jen Hwang | Z. Kobalava | F. Wyss | A. Sigurdsson | P. Otasevic | T. Forster | B. Manning | F. Medina | Brendan M. Everett | Julian Woelcke | T. Perlstein | T. Klemsdal | T. Thuren | R. Hilkert | T. Salko | Deepak Nema | T. Mayer | C. East | C. Mickel | P. Siostrzonek | H. Kultursay | A. Dalseg | B. Petrauskiene | L. Vida-Simiti | Susan Cheng | N. Wei | M. Ligueros | William Chang | S. Anker | M. Tan | L. Forgosh | Reena L. Pande | Huo Yong | R. Vettus | I. Veze | Leon Salvador | Barry Harris | Jaison Jose | S. Lal | S. Manfreda | Robert Glynn | M. Lainščak | Brendan M Everett | Robert J Glynn | Brendan Everett | Robert Glynn | Bindu Charmarthi | Renato Lopes | J. Scott | Georgia Tamesby | Tom Ponce | J. Kam | R. Saini | Kehur Banker | Panjat Nandy | Ronda Tawfik | Greg O'Neil | S. Manne | Pravin Jirvankar | Jean G Macfadyen | Prem Pais | Juey‐Jen Hwang

[1]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[2]  E. Bruera,et al.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. , 2014, The Lancet. Oncology.

[3]  N. Naykoo,et al.  Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non small cell lung cancer☆ , 2014, Meta gene.

[4]  P. Libby,et al.  Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial , 2012, Circulation.

[5]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[6]  Jennifer G. Robinson,et al.  The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.

[7]  Mark Woodward,et al.  Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012 .

[8]  A. Mantovani,et al.  Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.

[9]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[10]  Y. Carmi,et al.  Microenvironment-Derived IL-1 and IL-17 Interact in the Control of Lung Metastasis , 2011, The Journal of Immunology.

[11]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[12]  K. O'Byrne,et al.  The role of inflammation in the pathogenesis of non-small cell lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  J. Goedert,et al.  C-reactive protein and risk of lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Dinarello.  Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.

[15]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[16]  P. Allavena,et al.  Cellular and molecular pathways linking inflammation and cancer. , 2009, Immunobiology.

[17]  S. Bojesen,et al.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[19]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[20]  S. Dubinett,et al.  Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. , 2008, Critical reviews in oncology/hematology.

[21]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[22]  E. Voronov,et al.  Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? , 2008, Immunological reviews.

[23]  S. Akira,et al.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. , 2007, The Journal of clinical investigation.

[24]  A. Hofman,et al.  C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Alexander,et al.  Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .

[26]  Y. Carmi,et al.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions , 2006, Cancer and Metastasis Reviews.

[27]  Hongbing Shen,et al.  Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. , 2006, Cancer letters.

[28]  D. Phillips,et al.  Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. , 2005, Lung cancer.

[29]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[30]  F. Canzian,et al.  Polymorphisms of the interleukin‐1 β gene are associated with increased risk of non‐small cell lung cancer , 2004, International journal of cancer.

[31]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[33]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.